SCHEMBL9950191

SCHEMBL9950191

CN1CCN(CC2CC(n3cc(-c4cccc(OCC56CCC(CC5)O6)c4)c4c(N)ncnc43)C2)CC1=O

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 20/20 0.79
▸ KCNH2 Q12809 4/20 0.79
▸ INSR P06213 4/20 0.79
▸ PKN1 Q16512 1/20 0.79
▸ LCK P06239 3/20 0.59
▸ RET P07949 3/20 0.59
▸ EPHB4 P54760 2/20 0.59
▸ PDPK1 O15530 2/20 0.55
▸ KDR P35968 2/20 0.55
▸ PIK3CD O00329 1/20 0.55
▸ EPHA4 P54764 1/20 0.55
▸ EGFR P00533 1/20 0.55
▸ ERBB2 P04626 1/20 0.55
▸ LYN P07948 1/20 0.55
▸ MET P08581 1/20 0.55
▸ PDGFRB P09619 1/20 0.55
▸ KIT P10721 1/20 0.55
▸ FGFR1 P11362 1/20 0.55
▸ SRC P12931 1/20 0.55
▸ PDGFRA P16234 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9950194 1.00 IGF1R (0.79) IGF1RKCNH2INSRPKN1LCK
SCHEMBL1442875 0.90 IGF1R (0.77) IGF1RKCNH2INSRPKN1LCK
SCHEMBL1442869 0.90 IGF1R (0.77) IGF1RKCNH2INSRPKN1LCK
SCHEMBL1443738 0.90 IGF1R (0.77) IGF1RKCNH2INSRPKN1LCK
SCHEMBL1442870 0.90 IGF1R (0.77) IGF1RKCNH2INSRPKN1LCK
SCHEMBL12496778 0.88 IGF1R (0.77) IGF1RKCNH2INSRPKN1LCK
SCHEMBL12496777 0.88 IGF1R (0.77) IGF1RKCNH2INSRPKN1LCK
SCHEMBL1442178 0.88 IGF1R (1.00) IGF1RKCNH2INSRPKN1LCK
SCHEMBL9950720 0.88 IGF1R (0.69) IGF1RKCNH2INSRPKN1LCK
SCHEMBL9950721 0.88 IGF1R (0.69) IGF1RKCNH2INSRPKN1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2475668-A1 ETHER DERIVATIVES OF BICYCLIC HETEROARYLS Novartis AG (CH) 2012-07-18 — — EP disclosed
US-20120165310-A1 ETHER DERIVATIVES OF BICYCLIC HETEROARYLS NOVARTIS AG (CH) 2012-06-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165310-A1 ETHER DERIVATIVES OF BICYCLIC HETEROARYLS ETV6, CYP11B2, CYP11B1 IGF1R 2735/4885KCNH2 3657/4885INSR 695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback